European regulators ordered a recall of all batches of Amgen’s Tavneos (avacopan) after the European Commission formally canceled its marketing authorization earlier in the month. The action targets the vasculitis treatment tied to Amgen’s regulatory status across EU markets. The recall underscores how fast corporate and clinical operations can be disrupted when regulatory decisions change midstream. For biotech and pharma, it also raises the operational burden of managing supply, inventory disposition, and patient continuity as regulatory outcomes evolve. The key issue for clinicians and payers will be whether alternative therapies can absorb patients affected by the withdrawal and how remaining regulatory pathways might unfold.